NDA 203085 · Bayer Hlthcare
Stivarga
Regorafenib · Oral
NovelPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Feb 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2012
Sep 27, 2012
Approved uses
3
Original approval plus efficacy supplements
Registered trials
310
38 Phase 3, 45 recruiting
FAERS reports
11,611
10,468 serious, 2,373 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HEPATOTOXICITY • Severe and sometimes fatal hepatotoxicity has occurred in clinical trials [see Warnings and Precautions ( 5.1 )] . • Monitor hepatic function prior to and during treatment [see Warnings and Precautions ( 5.1 )]. • Interrupt and then reduce or discontinue STIVARGA for hepatotoxicity as manifested by elevated liver function tests or hepatocellular necrosis, depending upon severity and persistence [see Dosage and Administration ( 2.2 )] . WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. • Severe and sometimes fatal hepatotoxicity has occurred in clinical trials. ( 5.1 ) • Monitor hepatic function prior to and during treatment. ( 5.1 ) • Interrupt and then reduce or discontinue STIVARGA for hepatotoxicity as manifested by elevated liver function tests or hepatocellular necrosis, depending upon severity and persistence. ( 2.2 )
What it is approved for
From the label in effect Feb 9, 2026.
STIVARGA is a kinase inhibitor indicated for the treatment of adult patients with: • Metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy. ( 1.1 ) • Locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. ( 1.2 ) • Hepatocellular carcinoma (HCC) who have been previously treated with sorafenib ( 1.3 ) 1.1 Colorectal Cancer STIVARGA is indicated for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy. 1.2 Gastrointestinal Stromal Tumors STIVARGA is indicated for the treatment of adult patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. 1.3 Hepatocellular Carcinoma STIVARGA is indicated for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
Mechanism: Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, metastasis and tumor immunity. In in vitro biochemical or cellular assays, regorafenib or its major human active metabolites M-2 and M-5 inhibited the activity of RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAF V600E, SAPK2, PTK5, Abl and CSF1R at concentrations of regorafenib that have been achieved clinically. In in vivo...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 14, 2018 Supplement 8 · Efficacy OrphanLetterLabel
- Apr 27, 2017 Supplement 7 · Efficacy · priority review OrphanLabelLetterReview
- Sep 27, 2012 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanReviewLabelSummary Review
1 products under this application
- STIVARGA · REGORAFENIB 40MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Regorafenib" as an intervention, any sponsor and status, largest first.
- A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaPivotal-lookingRecruiting
Global Coalition for Adaptive ResearchAcademic, hospital or other
NCT03970447 · 2,250 participants (planned) · Start Jul 30, 2019 · Primary completion Jun 2028
Drug: Temozolomide; Lomustine and 8 more · For: Glioblastoma
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 63 sites in all
- FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcomaPivotal-lookingRecruiting
University of BirminghamAcademic, hospital or other
NCT04625907 · 1,672 participants (planned) · Start Sep 17, 2020 · Primary completion Jun 2030
Drug: Irinotecan; Actinomycin D and 7 more · For: Rhabdomyosarcoma
Sites: Brisbane, Australia; Camperdown, Australia; Clayton, Australia · 128 sites in all
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
- Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal CancerPivotal-lookingActive, not recruiting
ExelixisIndustry
NCT05425940 · 901 participants · Start Sep 7, 2022 · Primary completion Jun 16, 2026
Drug: XL092; Atezolizumab and 1 more · For: Colorectal Cancer
Sites: Jonesboro, Alabama; Phoenix, Arizona; Tucson, Arizona · 133 sites in all
- A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal CancerPivotal-lookingTerminated
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT05328908 · 769 participants · Start Apr 28, 2022 · Primary completion Jul 14, 2025
Drug: Nivolumab-relatlimab FDC; Regorafenib and 1 more · For: Colorectal Neoplasms
Sites: Springdale, Arkansas; Los Angeles, California; Norwich, Connecticut · 139 sites in all
- Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard TherapyPivotal-lookingCompleted
BayerBayer (BAYRY)
NCT01103323 · 760 participants · Start Apr 2010 · Primary completion Jul 2011
Drug: Regorafenib (Stivarga, BAY73-4506); Placebo · For: Metastatic Colorectal Cancer
Sites: Beverly Hills, California; Los Angeles, California; Mission Hills, California · 171 sites in all
Institut BergoniéAcademic, hospital or other
NCT03475953 · 747 participants (planned) · Start May 4, 2018 · Primary completion Dec 31, 2024
Drug: Phase 1 : Regorafenib; Phase 1 : Avelumab and 3 more · For: Colorectal Cancer Not MSI-H or MMR-deficient; GIST; Oesophageal or Gastric Carcinoma and 12 more
Sites: Bordeaux, France; Brest, France; Lyon, France · 7 sites in all
- Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus CetuximabPivotal-lookingCompleted
Ludwig-Maximilians - University of MunichAcademic, hospital or other
NCT02934529 · 673 participants · Start Mar 2015 · Primary completion Jan 30, 2025
Drug: Irinotecan; Folinic Acid and 8 more · For: Metastatic Colorectal Cancer
Sites: Munich, Germany
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use2,080
- fatigue1,778
- palmar-plantar erythrodysaesthesia syndrome1,446
- diarrhoea1,427
- decreased appetite1,097
- death1,007
- asthenia950
- dysphonia825
- nausea818
- pain in extremity774
- pyrexia757
- hypertension700
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 2 |
| 2012 | 119 |
| 2013 | 928 |
| 2014 | 810 |
| 2015 | 886 |
| 2016 | 653 |
| 2017 | 1,019 |
| 2018 | 1,150 |
| 2019 | 980 |
| 2020 | 962 |
| 2021 | 956 |
| 2022 | 870 |
| 2023 | 770 |
| 2024 | 694 |
| 2025 | 567 |
| 2026 | 245 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Stivarga (Regorafenib)
2024 spending
$96.4M
Beneficiaries
1,723
5,533 claims
Per beneficiary
$55,963
$266.34 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $109,102,678 |
| 2021 | $110,788,615 |
| 2022 | $118,540,814 |
| 2023 | $111,001,740 |
| 2024 | $96,423,433 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C.
Fakih MG, Salvatore L, Esaki T, et al. · N Engl J Med 2023 · Randomized Controlled Trial, Multicenter Study
- Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.
Dasari A, Lonardi S, Garcia-Carbonero R, et al. · Lancet 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.
Blay JY, Serrano C, Heinrich MC, et al. · Lancet Oncol 2020 · Clinical Trial, Phase III, Multicenter Study
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Grothey A, Van Cutsem E, Sobrero A, et al. · Lancet 2013 · Clinical Trial, Phase III, Multicenter Study
- Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020).
Haber PK, Puigvehí M, Castet F, et al. · Gastroenterology 2021 · Meta-Analysis, Research Support, N.I.H., Extramural
- Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma.
Davis LE, Bolejack V, Ryan CW, et al. · J Clin Oncol 2019 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Bayer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.